blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP3299390

EP3299390 - METHODS OF TREATING PSORIASIS USING IL-17 ANTAGONISTS [Right-click to bookmark this link]
StatusGrant of patent is intended
Status updated on  07.10.2024
Database last updated on 02.11.2024
FormerExamination is in progress
Status updated on  17.09.2024
FormerGrant of patent is intended
Status updated on  08.02.2024
FormerExamination is in progress
Status updated on  09.01.2024
FormerGrant of patent is intended
Status updated on  18.05.2023
FormerExamination is in progress
Status updated on  07.04.2023
FormerGrant of patent is intended
Status updated on  09.08.2022
FormerExamination is in progress
Status updated on  01.03.2022
FormerGrant of patent is intended
Status updated on  01.07.2021
FormerExamination is in progress
Status updated on  22.02.2019
FormerRequest for examination was made
Status updated on  05.10.2018
FormerThe application has been published
Status updated on  23.02.2018
Most recent event   Tooltip07.10.2024New entry: Communication of intention to grant a patent 
Applicant(s)For all designated states
Novartis AG
Lichtstrasse 35
4056 Basel / CH
[2018/13]
Inventor(s)01 / Guettner, Achim
Novartis Pharma AG
Postfach
4002 Basel / CH
02 / Machacek, Matthias
Novartis Pharma AG
Postfach
4002 Basel / CH
03 / Papavassilis, Charis
Novartis Pharma AG
Postfach
4002 Basel / CH
04 / Sander, Oliver
Novartis Pharma AG
Postfach
4002 Basel / CH
 [2018/13]
Representative(s)Carpmaels & Ransford LLP
One Southampton Row
London WC1B 5HA / GB
[N/P]
Former [2018/13]Rouquayrol, Céline Hélène
Novartis Pharma AG
Patent Department
4002 Basel / CH
Application number, filing date17195148.607.10.2011
[2018/13]
Priority number, dateUS20100391388P08.10.2010         Original published format: US 391388 P
[2018/13]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report 
No.:EP3299390
Date:28.03.2018
Language:EN
[2018/13]
Search report(s)(Supplementary) European search report - dispatched on:EP30.01.2018
ClassificationIPC:C07K16/24, A61K39/395, A61P17/06, A61K39/00
[2021/22]
CPC:
C07K16/244 (EP,CN,US); A61K39/395 (KR,RU); A61K39/3955 (US);
A61P17/06 (EP,RU); A61K2039/505 (EP,CN,US); A61K2039/545 (EP,CN,US);
C07K2317/34 (EP,CN,US); C07K2317/76 (EP,CN,US) (-)
Former IPC [2018/13]C07K16/24, A61K39/395
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2018/45]
Former [2018/13]AL,  AT,  BE,  BG,  CH,  CY,  CZ,  DE,  DK,  EE,  ES,  FI,  FR,  GB,  GR,  HR,  HU,  IE,  IS,  IT,  LI,  LT,  LU,  LV,  MC,  MK,  MT,  NL,  NO,  PL,  PT,  RO,  RS,  SE,  SI,  SK,  SM,  TR 
Extension statesBA28.09.2018
ME28.09.2018
TitleGerman:METHODEN ZUR BEHANDLUNG VON PSORIASIS UNTER VERWENDUNG VON IL-17 ANTAGONISTEN[2018/13]
English:METHODS OF TREATING PSORIASIS USING IL-17 ANTAGONISTS[2018/13]
French:PROCÉDÉS DE TRAITEMENT DU PSORIASIS A L'AIDE D'ANTAGONISTES DE IL-17[2018/13]
Examination procedure13.09.2018Amendment by applicant (claims and/or description)
28.09.2018Examination requested  [2018/45]
28.09.2018Date on which the examining division has become responsible
26.02.2019Despatch of a communication from the examining division (Time limit: M06)
14.08.2019Reply to a communication from the examining division
07.04.2021Cancellation of oral proceeding that was planned for 14.04.2021
14.04.2021Date of oral proceedings (cancelled)
02.07.2021Communication of intention to grant the patent
01.03.2022Disapproval of the communication of intention to grant the patent by the applicant or resumption of examination proceedings by the EPO
10.08.2022Communication of intention to grant the patent
05.04.2023Disapproval of the communication of intention to grant the patent by the applicant or resumption of examination proceedings by the EPO
19.05.2023Communication of intention to grant the patent
08.01.2024Disapproval of the communication of intention to grant the patent by the applicant or resumption of examination proceedings by the EPO
09.02.2024Communication of intention to grant the patent
17.07.2024Despatch of communication that the application is deemed to be withdrawn, reason: fee for grant / fee for printing not paid in time
17.09.2024Disapproval of the communication of intention to grant the patent by the applicant or resumption of examination proceedings by the EPO
08.10.2024Communication of intention to grant the patent
Parent application(s)   TooltipEP11764764.4  / EP2625199
Divisional application(s)EP20187002.9  / EP3792281
EP22186296.4  / EP4137514
Request for further processing for:The application is deemed to be withdrawn due to failure to fulfill actions required for granting the patent
17.09.2024Request for further processing filed
17.09.2024Full payment received (date of receipt of payment)
Request granted
25.09.2024Decision despatched
The application is deemed to be withdrawn due to failure to fulfill actions required for granting the patent
08.01.2024Request for further processing filed
08.01.2024Full payment received (date of receipt of payment)
Request granted
16.01.2024Decision despatched
The application is deemed to be withdrawn due to failure to fulfill actions required for granting the patent
05.04.2023Request for further processing filed
05.04.2023Full payment received (date of receipt of payment)
Request granted
13.04.2023Decision despatched
The application is deemed to be withdrawn due to failure to fulfill actions required for granting the patent
01.03.2022Request for further processing filed
01.03.2022Full payment received (date of receipt of payment)
Request granted
14.03.2022Decision despatched
Fees paidRenewal fee
06.02.2018Renewal fee patent year 03
06.02.2018Renewal fee patent year 04
06.02.2018Renewal fee patent year 05
06.02.2018Renewal fee patent year 06
06.02.2018Renewal fee patent year 07
11.10.2018Renewal fee patent year 08
15.10.2019Renewal fee patent year 09
14.10.2020Renewal fee patent year 10
29.09.2021Renewal fee patent year 11
28.09.2022Renewal fee patent year 12
27.09.2023Renewal fee patent year 13
26.09.2024Renewal fee patent year 14
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Documents cited:Search[A]WO2006013107  (NOVARTIS AG [CH], et al);
 [A]WO2007070750  (LILLY CO ELI [US], et al);
 [A]WO2007149032  (ASTRAZENECA AB [SE], et al);
 [A]WO2010034443  (HOFFMANN LA ROCHE [CH], et al);
by applicantWO2006013107
 US2009280131
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.